Brief: Precigen Announces Full FDA Approval Of Papzimeos
15/08/2025 12:23
Aug 15 (Reuters) - Precigen Inc PGEN.O: PRECIGEN ANNOUNCES FULL FDA APPROVAL OF PAPZIMEOS (ZOPAPOGENE IMADENOVEC-DRBA), THE FIRST AND ONLY APPROVED THERAPY FOR THE TREATMENT OF ADULTS WITH RECURRENT RESPIRATORY PAPILLOMATOSIS Source text: ID:nPn3dr0Gma Further company coverage: PGEN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precigen
See all newsBrief: Precigen Receives FDA Platform Technology Designation For Adenoverse Platform
Precigen, Inc. reports results for the quarter ended June 30 - Earnings Summary
Precigen posts quarterly profit as PAPZIMEOS sales surge
Precigen Inc expected to post a loss of 1 cent a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Advanced Energy, Bel Fuse, Cerebras